1. Home
  2. AGEN vs STIM Comparison

AGEN vs STIM Comparison

Compare AGEN & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.79

Market Cap

126.8M

Sector

Health Care

ML Signal

HOLD

Logo Neuronetics Inc.

STIM

Neuronetics Inc.

HOLD

Current Price

$1.52

Market Cap

136.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
STIM
Founded
1994
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.8M
136.3M
IPO Year
2000
2018

Fundamental Metrics

Financial Performance
Metric
AGEN
STIM
Price
$3.79
$1.52
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$14.50
$7.00
AVG Volume (30 Days)
450.4K
1.9M
Earning Date
11-10-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,829,000.00
$129,873,000.00
Revenue This Year
$67.15
$101.67
Revenue Next Year
N/A
$10.87
P/E Ratio
N/A
N/A
Revenue Growth
N/A
78.61
52 Week Low
$1.38
$1.05
52 Week High
$7.34
$5.92

Technical Indicators

Market Signals
Indicator
AGEN
STIM
Relative Strength Index (RSI) 38.61 42.42
Support Level $3.82 $1.28
Resistance Level $4.12 $1.51
Average True Range (ATR) 0.20 0.12
MACD -0.04 0.06
Stochastic Oscillator 0.58 76.81

Price Performance

Historical Comparison
AGEN
STIM

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About STIM Neuronetics Inc.

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Share on Social Networks: